LEO Pharma

Olivier Bohuon elected to LEO Pharma’s Board of Directors

Del

LEO Pharma expands its Board of Directors with Olivier Bohuon who will join as vice chairman. With extensive experience in global pharmaceuticals and medical technology, Bohuon will contribute significantly to realising LEO Pharma’s strategy of being a global leader in medical dermatology.

Olivier Bohuon, new vice chairman of  LEO Pharma’s Board of Directors.
Olivier Bohuon, new vice chairman of LEO Pharma’s Board of Directors.

Ballerup, Denmark, August 28, 2018 – On August 27 an extraordinary general meeting elected Olivier Bohuon as a new member of LEO Pharma’s Board of Directors. He will serve as the Board of Directors’ new vice chairman.

“I am excited to welcome Olivier Bohuon to LEO Pharma’s Board of Directors,” said Jukka Pertola, Chairman of LEO Pharma’s Board of Directors. “Olivier brings extensive strategic and commercial expertise in the global pharma industry. This will benefit LEO Pharma greatly as we are expanding into new innovative treatments in our ambition of being a global leader in medical dermatology,” Pertola continued.

“LEO Pharma is a company with a very strong vision. Its focus area of medical dermatology is strongly growing, highly competitive and benefiting from scientific advances in biotechnology. I am delighted to be able to help LEO Pharma succeed with its ambitious strategy,” said Olivier Bohuon.

Olivier Bohuon brings extensive experience in the global pharmaceutical and med-tech industry. He is board member of Smiths Group plc, senior independent director at Shire plc, supervisory board member at Virbac SA, and member of the National Pharmacy Academy and the Academy of Technologies. From 2011 to May 2018 Bohuon served as CEO of medical equipment specialist Smith & Nephew plc. Before that, he held positions as CEO at Laboratories Pierre Fabre, EVP, pharmaceutical products at Abbott Laboratories and SVP, director of European Commercial Operations at GlaxoSmithKline.

- ENDS -

Kontakter

Media Contact
Henrik Kyndlev
henrik.kyndlev@leo-pharma.com
+45 3140 6180

Billeder

Olivier Bohuon, new vice chairman of  LEO Pharma’s Board of Directors.
Olivier Bohuon, new vice chairman of LEO Pharma’s Board of Directors.
Download

Information om LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 130 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,200 people worldwide. For more information, visit www.leo-pharma.com

LinkedIn: www.linkedin.com/company/leo-pharma
YouTube: www.youtube.com/leopharmaglobal
Twitter: www.twitter.com/leohealthyskin

Følg pressemeddelelser fra LEO Pharma

Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.

Flere pressemeddelelser fra LEO Pharma

LEO Pharma and MorphoSys Expand Strategic Alliance to Develop Peptide-derived Therapeutics17.9.2018 22:34pressemeddelelse

LEO Pharma A/S, a global leader in medical dermatology, and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) today announced an expansion of their existing strategic alliance to include peptide-derived therapeutics. The objective of the alliance is to identify novel, peptide-derived therapeutics for unmet medical needs that will be valuable additions to both companies’ pipelines. This alliance expands the existing partnership of the two companies signed in November 2016 to jointly discover and develop antibody-based therapies in dermatology.

LEO Pharma A/S indlicenserer lovende ny lægemiddelkandidat fra JW Pharmaceutical til oral behandling af atopiske dermatitis24.8.2018 10:23pressemeddelelse

LEO Pharma får eksklusivrettigheder til at udvikle og kommercialisere JW1601 på det globale marked ekskl. Korea. JW1601 er en ny lægemiddelkandidat beregnet til oral behandling af atopisk dermatitis. JW Pharmaceutical modtager op til 402 mio. USD på forhånd og i milepælsbetalinger. Udover milepælsbetalinger vil der blive tildelt royalty.

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.

Besøg vores nyhedsrum